LB069 - DIABETES SARCOPENIA ALGORITHM IDENTIFIES SARCOPENIA AMONG PATIENTS WITH TYPE II DIABETES MELLITUS WITH HIGH ACCEPTABILITY AMONG HEALTHCARE PROFESSIONALS

LB069

DIABETES SARCOPENIA ALGORITHM IDENTIFIES SARCOPENIA AMONG PATIENTS WITH TYPE II DIABETES MELLITUS WITH HIGH ACCEPTABILITY AMONG HEALTHCARE PROFESSIONALS

F. J. Tarazona-Santabalbina¹, J. M. García-Almeida ², F. Garrachón Vallo³, G. Guzmán Rolo^4,*, C. Grande⁴, A. R. Sharn⁵, D. de Luis Román⁶

¹Geriatrics Department, University Hospital of la Ribera, Valencia, ²Clinical Management Unit of Endocrinology and Nutrition, Virgen de la Victoria Clinical Hospital, Málaga, ³Internal Medicine Department, Virgen de Macarena University Hospital, Seville, ⁴Global Medical Affairs and Research, Abbott, Madrid, Spain, ⁵Global Medical Affairs and Research, Abbott, Colombus, United States, ⁶Investigation Center of Endocrinology and Nutrition, University of Valladolid, Valladolid, Spain

Rationale: Recent findings highlight more than half of people >70 years with type II diabetes mellitus (T2DM) are at risk of sarcopenia. Tools such as Global Leadership Initiative on Malnutrition (GLIM) may miss muscle loss among those with sarcopenia secondary to T2DM.

Methods: Cross-sectional, observational study evaluating feasibility of the Diabetes Sarcopenia Algorithm (DSA) developed by a diabetes expert panel for use among outpatients with T2DM. Patients from 4 Spanish hospitals’ endocrinology, internal medicine, or geriatric clinics were screened for diabetic sarcopenia (DS) via DSA and evaluated for malnutrition via GLIM. Acceptability among healthcare professionals (HCPs) with at least 20 uses of DSA was evaluated using: System Usability Scale (SUS) (scores > 68 acceptable) and Net Promoter Score (NPS) (scores ≥ 50 excellent).

Results: Most patients (N=213) were male (53.5%), mean age 75.6 (±11.3) years, and mean BMI 25.5 (±3.0) kg/m². Nearly two-thirds had micro- (68.0%) or macro- (67.2%) vascular complications and 52.5% of patients had DS classified as stage I: 7.8% (DS without complications), stage II: 18.5% (DS with complications), stage III: 28.2% (DS with functional impairment), or stage IV: 45.6% (DS with functional impairment and complications). Among HCPs, DSA scored 77.9% (high) for usability and +60 (excellent) for NPS.

Conclusion: Results indicate high acceptability of DSA among HCPs and a high prevalence of DS in outpatients with T2DM. DSA highlights an opportunity for identifying and intervening with T2DM patients with impaired muscle mass. Future research utilizing DSA for screening, nutrition education, oral nutrition supplements with muscle specific ingredients, and follow-up will help understand how nutrition-focused programs can impact T2DM patient health, clinical, and economic outcomes.

Disclosure of Interest: F. J. Tarazona-Santabalbina: None declared, J. M. García-Almeida : None declared, F. Garrachón Vallo: None declared, G. Guzmán Rolo Other: Germán Guzmán Rolo was employee of Abbott Laboratories while the wok was completed, C. Grande Other: Cristina Grande was employee of Abbott Laboratories while the work was completed., A. R. Sharn Other: Amy R. Sharn was employee of Abbott Laboratories while the work was completed., D. de Luis Román: None declared